Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ)
CNY 6.96
(0.72%)
CNY 6.96
(0.72%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 417.61 Million CNY | -4.68% |
| 2022 | 370.04 Million CNY | 28.33% |
| 2021 | 294.93 Million CNY | -13.87% |
| 2020 | 162.26 Million CNY | 55.43% |
| 2019 | -400.79 Million CNY | -43.83% |
| 2018 | 373.47 Million CNY | 4.47% |
| 2017 | 285.61 Million CNY | 46.22% |
| 2016 | 260.87 Million CNY | 67.51% |
| 2015 | 142.18 Million CNY | 53.6% |
| 2014 | 95.12 Million CNY | 18.21% |
| 2013 | 71.08 Million CNY | -10.49% |
| 2012 | 91.52 Million CNY | 37.33% |
| 2011 | 66.53 Million CNY | 18.0% |
| 2010 | 59.25 Million CNY | 20.98% |
| 2009 | 49.88 Million CNY | 7.26% |
| 2008 | 44.95 Million CNY | -13.31% |
| 2007 | 52.92 Million CNY | 33.04% |
| 2006 | 38.88 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 43.28 Million CNY | -58.69% |
| 2024 Q1 | 93.85 Million CNY | 22.62% |
| 2024 Q2 | 88.41 Million CNY | -7.89% |
| 2023 Q3 | 52.04 Million CNY | -40.13% |
| 2023 Q1 | 119.77 Million CNY | 378.03% |
| 2023 Q4 | 81.83 Million CNY | 57.22% |
| 2023 FY | - CNY | -4.68% |
| 2023 Q2 | 86.94 Million CNY | -27.41% |
| 2022 Q3 | 64.99 Million CNY | -29.47% |
| 2022 FY | - CNY | 28.33% |
| 2022 Q4 | 25.05 Million CNY | -61.45% |
| 2022 Q2 | 92.15 Million CNY | -6.24% |
| 2022 Q1 | 98.28 Million CNY | 56.09% |
| 2021 Q3 | 4.42 Million CNY | -93.5% |
| 2021 Q1 | 66.25 Million CNY | 10.34% |
| 2021 Q2 | 68.09 Million CNY | 2.77% |
| 2021 Q4 | 62.96 Million CNY | 1323.6% |
| 2021 FY | - CNY | -13.87% |
| 2020 Q3 | 71.76 Million CNY | 12.85% |
| 2020 Q2 | 63.59 Million CNY | -13.86% |
| 2020 Q1 | 73.82 Million CNY | 181.27% |
| 2020 FY | - CNY | 55.43% |
| 2020 Q4 | 60.04 Million CNY | -16.33% |
| 2019 Q1 | 95.96 Million CNY | 4.47% |
| 2019 FY | - CNY | -43.83% |
| 2019 Q3 | 48.29 Million CNY | -47.76% |
| 2019 Q4 | -90.83 Million CNY | -288.09% |
| 2019 Q2 | 92.45 Million CNY | -3.66% |
| 2018 Q1 | 83.43 Million CNY | 27.9% |
| 2018 FY | - CNY | 4.47% |
| 2018 Q3 | 66.3 Million CNY | -20.43% |
| 2018 Q4 | 91.85 Million CNY | 38.54% |
| 2018 Q2 | 83.33 Million CNY | -0.12% |
| 2017 Q2 | 48.16 Million CNY | -60.26% |
| 2017 Q1 | 121.21 Million CNY | 29.85% |
| 2017 Q3 | 47.11 Million CNY | -2.19% |
| 2017 FY | - CNY | 46.22% |
| 2017 Q4 | 65.23 Million CNY | 38.46% |
| 2016 Q1 | 31.38 Million CNY | -43.39% |
| 2016 Q2 | 72.86 Million CNY | 132.13% |
| 2016 FY | - CNY | 67.51% |
| 2016 Q3 | 24.45 Million CNY | -66.44% |
| 2016 Q4 | 93.34 Million CNY | 281.72% |
| 2015 FY | - CNY | 53.6% |
| 2015 Q4 | 55.44 Million CNY | 204.66% |
| 2015 Q2 | 31.98 Million CNY | 117.24% |
| 2015 Q1 | 14.72 Million CNY | -45.5% |
| 2015 Q3 | 18.19 Million CNY | -43.1% |
| 2014 Q2 | 12.75 Million CNY | -39.88% |
| 2014 Q3 | 4.49 Million CNY | -64.74% |
| 2014 Q4 | 27.01 Million CNY | 500.7% |
| 2014 FY | - CNY | 18.21% |
| 2014 Q1 | 21.21 Million CNY | 16.99% |
| 2013 Q4 | 18.13 Million CNY | 274.58% |
| 2013 Q2 | 17.51 Million CNY | -18.3% |
| 2013 Q3 | 4.84 Million CNY | -72.36% |
| 2013 FY | - CNY | -10.49% |
| 2013 Q1 | 21.43 Million CNY | -40.69% |
| 2012 Q3 | 9.9 Million CNY | -48.81% |
| 2012 FY | - CNY | 37.33% |
| 2012 Q4 | 36.14 Million CNY | 264.86% |
| 2012 Q1 | 14.62 Million CNY | -42.57% |
| 2012 Q2 | 19.35 Million CNY | 32.36% |
| 2011 Q3 | 11.57 Million CNY | -60.95% |
| 2011 Q1 | 12.3 Million CNY | -13.42% |
| 2011 Q2 | 29.64 Million CNY | 140.9% |
| 2011 Q4 | 25.45 Million CNY | 119.89% |
| 2011 FY | - CNY | 18.0% |
| 2010 Q2 | 12.09 Million CNY | 15.7% |
| 2010 Q4 | 14.21 Million CNY | -14.0% |
| 2010 Q3 | 16.53 Million CNY | 36.62% |
| 2010 Q1 | 10.45 Million CNY | 62.06% |
| 2010 FY | - CNY | 20.98% |
| 2009 Q1 | -10.66 Million CNY | -525.65% |
| 2009 Q4 | 6.45 Million CNY | -58.54% |
| 2009 Q3 | 15.56 Million CNY | -45.75% |
| 2009 Q2 | 28.69 Million CNY | 369.1% |
| 2009 FY | - CNY | 7.26% |
| 2008 FY | - CNY | -13.31% |
| 2008 Q3 | 10.83 Million CNY | 0.0% |
| 2008 Q4 | 2.5 Million CNY | -76.88% |
| 2007 FY | - CNY | 33.04% |
| 2006 FY | - CNY | 0.0% |